Heterogeneity of Head and Neck Squamous Cell Carcinoma Stem Cells.
Adv Exp Med Biol
; 1139: 23-40, 2019.
Article
em En
| MEDLINE
| ID: mdl-31134493
ABSTRACT
Current systemic cancer treatment in head and neck squamous cell carcinoma (HNSCC) is moving toward more personalized approaches such as de-escalation protocols human-papilloma-virus dependent HNSCC or application of checkpoint inhibitors. However, these treatments have been challenged by cancer stem cells (CSC), a small population within the bulk tumor, which are leading to treatment failure, tumor recurrence, or metastases. This review will give an overview of the characteristics of HNSCC-CSC. Specifically, the mechanisms by which HNSCC-CSC induce tumor initiation, progression, recurrence, or metastasis will be discussed. Although evidence-based treatment options targeting HNSCC-CSC specifically are still being sought for, they warrant a promise for additional and sustainable treatment options where for HNSCC patients where others have failed.
Palavras-chave
Aldehyde dehydrogenase I; CSC-directed therapeutic; Cancer stem cell (CSC); Epidermal growth factor receptor (EGFR); Epithelial-to-mesenchymal transition (EMT); Head and neck squamous cell carcinoma (HNSCC); Immune evasion; Immune response; Immunotherapy; Mesenchymal-to-epithelial transition (MET); PD-1; PD-L1; Tumor microenvironment
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Células-Tronco Neoplásicas
/
Carcinoma de Células Escamosas de Cabeça e Pescoço
Tipo de estudo:
Guideline
Limite:
Humans
Idioma:
En
Revista:
Adv Exp Med Biol
Ano de publicação:
2019
Tipo de documento:
Article
País de afiliação:
Alemanha